Neuraxis Inc (NRXS) Financier

NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 21 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. The company focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.